Blue Sky Vaccines

Blue Sky Vaccines is a clinical-stage biotechnology company based in Vienna, Austria, specializing in the development of innovative viral vaccines and oncolytic therapies. The company utilizes its proprietary delNS1 technology platform, which involves the deletion of the non-structural protein 1 (NS1) from the influenza virus to create replication-deficient vectors that stimulate a potent interferon-mediated immune response. Their pipeline includes candidates for seasonal and pandemic influenza, as well as oncolytic virus programs targeting various solid tumors. By leveraging the natural properties of viral vectors, Blue Sky Vaccines aims to provide more effective and safer alternatives to traditional vaccination and cancer treatment methods.